This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Letters to the Editor

Gabapentin for the Treatment of Patients With Somatization Disorder

Javier Garcia-Campayo and Concepcion Sanz-Carrillo

Published: June 1, 2001

Article Abstract

Letter to the Editor

Sir: Somatization disorder is characterized by a pattern of multiple, clinically significant somatic complaints that cannot be fully explained by any known medical condition. The pharmacologic treatment of somatization disorder has scarcely been investigated owing to methodological problems, and no open or controlled trial has been conducted in patients with somatization disorder. Since pain is the most frequent symptom in somatization disorder, we selected gabapentin because it has demonstrated efficacy in patients with organic pain.


Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Volume: 62

Quick Links: Neurologic and Neurocognitive , Seizure

Sign-up to stay
up-to-date today!

SUBSCRIBE

Already registered? Sign In

Case Report

Safety and Tolerability of Concomitant Intranasal Esketamine Treatment With Irreversible, Nonselective MAOIs: A Case Series

Three cases suggest that concomitant use of intranasal esketamine with an irreversible, nonselective MAOI is safe in...

Read More...